Pay in 4 interest-free payments of $7.29 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
doi: 10.1073/pnas.0510352103 40
Cerebrolysin's Position: Decades of clinical use across 40+ countries with established safety and efficacy data Meta-analyses and Cochrane systematic reviews the highest levels of clinical evidence Known limitations: complex mixture makes precise mechanism attribution difficult, not FDA-approved, requires IV/IM administration Represents validated but incrementally effective neurotrophic therapy Dihexa's Position: Exceptional mechanistic novelty HGF/c-Met potentiation at picomolar concentrations is a genuinely unique pharmacological finding if confirmed Entirely preclinical with no human data of any kind Foundational research compromised by expression of concern and retraction the core evidence base is actively questioned Theoretical safety concerns (c-Met oncogenesis) that have not been addressed experimentally Represents frontier neuroscience that has not survived the basic tests of scientific reproducibility For Researchers: Cerebrolysin offers a clinically validated tool for studying neurotrophic effects in humans, supported by the strongest available evidence
Each softgel capsule contains: proprietary blend of glutathione and essential phospholipid: .375 mg Setria glutathione..250 mg Phospholipid complex .125 mg Other ingredients: gelatin capsule (gelatin, glycerin, water), extra virgin olive oil, beeswax, calcium carbonate
Decyanation of vitamin B12 by a trafficking chaperone
Similar products Trizomal Glutathione Apex Energetics, Inc 150 Milliliters $N/A (MSRP) Already have an account
"Clinical Vitamin B12 Deficiency
US$ 27.67
US$ 24.26
US$ 20.88
US$ 28.29
.png)
US$ 22.38
